trial

Extract of Ginkgo Biloba and Tardive Dyskinesia

NCTId NCT00672373
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 3 · Completed
Enrollment 157 (actual)
Sponsored by Beijing HuiLongGuan Hospital
Primary completion 2007-05
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 3
Status
Completed
Enrollment
157 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2006-12
Primary completion
2007-05
Eligibility
ALL · 18 Years · 60 Years

Interventions & indications

Drugs
Extract of Ginkgo Biloba (EGb-761 capsules)

Sponsors

Beijing HuiLongGuan HospitalLead Sponsor
Peking UniversityCollaborator

Investigators

2
Yunlong Tan, PhdPrincipal Investigator
Dongfeng Zhou, ProfessorStudy Chair

Sites

1 total
Beijing, China

Linked catalysts

1
Extract of Ginkgo Biloba and Tardive Dyskinesia — primary completion2007-05

Facts & assertions

4 sourced
Enrollment
157
Phase
PHASE3
Primary Completion Date
2007-05
Status
COMPLETED
relationships
The graph out of here
drug
Extract of Ginkgo Biloba (EGb-761 capsules)
drug
lead_sponsor
Beijing HuiLongGuan Hospital
company
collaborator
Peking University
company
indication
Schizophrenia
indication
Tardive Dyskinesia
indication
Schizophrenia
indication
investigator
Yunlong Tan, Phd
person
Dongfeng Zhou, Professor
person